Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

15 February 2022: Original Paper

Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT)

Katarzyna Zielińska 1ABCDEF* , Leszek Kukulski 2ACDF , Marta Wróbel 1AF , Piotr Przybyłowski 3ACDF , Dominika Rokicka 1AF , Krzysztof Strojek 1ACDE

DOI: 10.12659/AOT.933420

Ann Transplant 2022; 27:e933420

Table 1 Characteristics of the sample group divided into 4 subgroups (Excel by Microsoft 365).

Division
Without diabetesDiabetes type 2HyperglycemiaNODAT
Number of patients299 (62.7%)68 (14.3%)22 (4.6%)88 (18.4%)
Recipient sex (male) – no. (%)245 (81.9%)57 (83.8%)15 (68.2%)70 (79.6%)
Recipient age – years42.7±14.252.7±8.246.5±11.752.2±10.3
BMI – kg/m
 BMI at discharge23.3±3.525.6±3.325.6±3.325.6±3.3
 BMI at 1y follow-up25.3±4.027.5±4.027.5±4.027.5±4.0
 BMI at last available follow-up26.0±4.828.3±4.228.3±4.228.3±4.2
Increase in body weight in 2y after OHT by more than 5 kg – no. (%)230 (76.9%)43 (63.2%)14 (63.6%)42 (47.7%)
Ischemic – no. (%)94 (31.4%)34 (50%)9 (40.9%)52 (59.9%)
eGFR – mL/min/1.73 m94.0±40.079.4±30.690.9±27.578.8±29.9
Dyslipidemia – no. (%)52 (17.4%)27 (39.7%)9 (40.9%)30 (34.1%)
CMV seropositivity - no. (%)52 (17.4%)19 (28.0%)3 (13.6%)20 (22.7%)
Hypotensive pharmacotherapy – no. (%)40 (13.4%)14 (20.6%)8 (36.4%)25 (28.4%)
Levothyroxine therapy – no. (%)29 (9.7%)5 (7.4%)1 (4.50%)10 (11.4%)
Cyclosporine immunosuppressive scheme – no. (%)38 (12.71%)11 (16.18%)11 (50%)25 (28.41%)
Statins therapy – no. (%)148 (49.5%)45 (66.18%)18 (81.8%)73 (82.95%)
Steroid therapy
 6 mth posttransplant150 (50.2%)54 (79.41%)22 (100%)80 (90.91%)
 12 mth posttransplant62 (20.7%)25 (36.8%)13 (59.1%)23 (26.1%)
 24 mth posttransplant17 (5.7%)11 (16.2%)8 (36.4%)9 (10.2%)
ISHLT >3a at discharge – no. (%)96 (20.1%)28 (5.9%)16 (3.4%)52 (10.9%)
The episode numer of ISHLT >3a during the 1 year post-transplantation – no. (%)
 091 (30.4%)23 (33.8%)3 (13.6%)29 (33%)
 173 (24.4%)26 (38.2%)12 (54.5%)30 (34.1%)
 255 (18.4%)6 (8.8%)4 (18.2%)16 (18.2%)
 344 (14.7%)3 (4.4%)1 (4.5%)9 (10.2%)
 419 (6.4%)5 (7.4%)2 (9.1%)4 (4.5%)
 511 (3.7%)1 (1.5%)0 (0.0%)0 (0.0%)
 62 (0.7%)3 (4.4%)0 (0.0%)0 (0.0%)
 72 (0.7%)0 (0.0%)0 (0.0%)0 (0.0%)
 81 (0.3%)1 (1.5%)0 (0.0%)0 (0.0%)

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358